Continuity of Care Exceptions: How to Keep Your GLP-1 After a Formulary Change

If your health plan suddenly removes your GLP-1 drug from its formulary or adds new restrictions, you can ask for a “continuity of care” or “formulary exception” so treatment is not interrupted. Federal law gives continuing care patients up to 90 days of protected access, and most plans must decide expedited appeals within 72 hours. Submit a clear medical-necessity letter from your prescriber, meet each deadline, and escalate to external review if needed. If all appeals fail, manufacturer self-pay programs can cap monthly costs while you seek new coverage.

• Part D and commercial plans must give at least 60 days’ advance written notice before removing a covered drug or escalating its tier costs (cms.gov).
• Continuity-of-care rules let continuing care patients keep the same drug for up to 90 days after network or formulary termination (uscode.house.gov).
• Expedited formulary exception decisions are due within 72 hours, and standard requests within seven calendar days (cms.gov).
• An external review by an independent reviewer must issue a final decision within 72 hours when the case is medically urgent (healthcare.gov).
• Wegovy self-pay pricing is $349 per month for standard doses and $399 for Wegovy HD 7.2 mg through NovoCare home delivery (novocare.com).
• Zepbound self-pay prices start at $299 per month for 2.5 mg and $399 for 5 mg through LillyDirect, with higher doses at $449 (zepbound.lilly.com).

What a Continuity-of-Care Exception Does

Continuity of care means your treatment feels seamless even when the insurer’s rules change. In federal law, it lets a continuing care patient keep receiving the same drug or provider services for up to 90 days after the plan terminates coverage (uscode.house.gov). Continuity bridges the gap while you and your prescriber pursue a permanent solution, such as a formulary exception, alternative drug, or new plan.

Definition (40 words): Continuity of care is one patient experiencing care over time as connected and coherent with his or her health needs and personal circumstances (Waibel et al., 2016). For medication access, it prevents abrupt stops that could endanger your health.

Most states embed similar protections in insurance codes, but the federal rule applies to nearly all commercial and employer plans. Medicare Part D handles medication transitions separately through its 30-day temporary-fill policy (see table below).

Why Plans Drop GLP-1 Drugs Mid-year

Plans adjust formularies to control cost and respond to drug-shortage or safety updates. GLP-1 list prices exceed $900 per monthly pen, so insurers renegotiate rebates frequently. During 2025-2026, several large pharmacy benefit managers moved Wegovy and Zepbound to higher tiers or excluded them for weight loss, citing budget impact.

Common triggers:

• Rebate renegotiation: a rival brand offers deeper discounts.
• Utilization spikes: claims volume exceeds actuarial projections.
• Drug shortage alerts: FDA shortage listings may prompt a step-therapy edit.
• Employer carve-outs: self-funded groups can opt out of weight-loss coverage anytime.

Whatever the reason, federal marketing guidance still requires 60-day advance notice (cms.gov).

Who Qualifies for Transitional Coverage

You must be a “continuing care patient” and clinically unstable without the drug. The law lists serious and complex chronic illnesses as qualifying conditions (uscode.house.gov). Obesity with comorbidities (sleep apnea, heart disease, type 2 diabetes) generally meets the standard when you are mid-titration or have documented weight-regain risk.

Key eligibility points:

• On treatment ≥ 1 month: plans rarely grant continuity to brand-new starts.
• Risk of harm if stopped: prescriber must state in writing that stopping the GLP-1 could cause serious health decline.
• No similarly effective covered alternative: for example, switching from Ozempic to Trulicity may be reasonable for diabetes but not if weight-loss is the clinical goal.

How to File a Formulary Exception or Appeal

The process starts with your prescriber. Most plans accept the CMS Model Coverage Determination Request Form, but a simple letter that answers every criterion works as well. Include:

Bold sub-headers inside the letter:

• Diagnosis and ICD-10 code: e.g., E66.01 morbid obesity.
• Treatment history: doses, start date, documented weight loss or A1c change.
• Medical necessity rationale: why step-therapy alternatives are ineffective or unsafe.
• Risk of discontinuation: rebound weight gain, glycemic loss of control, or depression relapse.

Fax or upload the packet and request an expedited review if stopping the drug may jeopardize life or daily function. The plan must decide within 72 hours (expedited) or seven days (standard) (cms.gov).

Need a template? See our detailed appeal letter guide.

Timeline: From Notice to Final Decision

Federal rules lock in specific clocks. Missing any step lets the plan close your case.

If the Plan Says No: External Review and Next Steps

You have the right to take the dispute to an independent reviewer. Under the Affordable Care Act, every state must offer an external review process; federally administered reviews decide urgent cases within 72 hours (healthcare.gov). Collect the plan denial letter (often called an EOB), your original medical-necessity letter, and any new labs or progress notes before filing.

Escalation ladder:

1. Internal appeal level 1: written request.
2. Internal appeal level 2: plan review panel (some states skip this).
3. External review: state-contracted IRO or the HHS MAXIMUS program.

If external review upholds the plan, you may still qualify for temporary coverage under the Medicare GLP-1 Bridge (if you are on Medicare) or switch to an employer plan open to weight-loss drugs.

Other Ways to Afford Your GLP-1 During a Gap

Manufacturer self-pay programs can be cheaper than retail list price while appeals grind on.

You can also ask your prescriber to fax the script to NovoCare or LillyDirect directly. These cash programs bypass insurance, so payments do not count toward deductibles or OOP maximums.

Looking for more cost tactics? Read our cash-pay survival guide.